Summary
Amperozide (FG 5606; N-ethyl-4-[4′,4′-bis(p-fluorophenyl) butyl]-1-piperazinecarboximide) is a new putatively antipsychotic compound with a postulated 5-HT2 antagonistic profile. Somewhat surprisingly amperozide dose dependently induced a behavioural stimulation in reserpinized and in nonpretreated rats. The behaviour consisted of both forward and backward locomotion as well as forepaw circling and a grooming like behaviour. Since the behavioural pattern clearly differ from that produced by classical dopaminergic or serotonergic agonists (e. g. apomorphine or 8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT), and has not been previously reported, we decided to investigate the origin of this effect.
In the behavioural paradigms it was not possible to antagonize the amperozide stimulation in reserpinized rats with the dopamine receptor blockers haloperidol, raclopride or R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepine, SCH 23390. Neither the 5-HT2 receptor blocking agent ritanserin nor the tryptophan and tyrosine hydroxylase inhibitor DL-3,4-dihydroxy-phenyl-α-propylacetamide, H22/54, could block the motoric stimulation or the forepaw circling behaviour produced by amperozide. However, the noradrenaline synthesis inhibitor bis- (4-methyl-1-homopiperazinylthiocarbonyl)-disulfide, FLA 63, as well as the α-adrenoceptor antagonist phenoxy-benzamine, could partly inhibit the locomotor stimulation. Hence, noradrenaline seems to be, at least in part, involved in the behavioural stimulatory effect of amperozide. synthesis rate (DOPA formation) in normal or reserpinized animals in the striatal or the limbic brain regions. In reserpinized animals amperozide also failed to antagonize the decrease in DOPA formation after apomorphine and 3-hydroxy-benzylhydrazine HCl, NSD 1015, in these regions. Thus, amperozide failed to show agonistic or antagonistic action on central dopamine receptors. However, in the noradrenaline rich cortical region amperozide induced an increase in DOPA accumulation. The compound also increased the levels of normetanephrine as well as antagonized the decrease in DOPA accumulation by clonidine in the cortical brain region. Amperozide also increased the disappearence rate of noradrenaline after inhibitor of tyrosine hydroxylase by α-methyl-para-tyrosine. These data suggest that, biochemically, amperozide has got α2 antagonistic properties. However, it is not evident that these biochemical properties are responsible for the behavioural effects of amperozide.
Similar content being viewed by others
References
Andén NE, Strömbom U (1974) Adrenergic receptor blocking agents: Effects on central noradrenaline and dopamine receptors and on motor activity. Psychopharmacologia (Berl) 38: 91–103
Andén NE, Grabowska M, Strömbom U (1976) Different alpha-adrenoceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents. Naunyn-Schmiedeberg's Arch Pharmacol 292:43–52
Björk A, Olsson NG, Christensson E, Martinsson K, Olsson O (1988) Effects of amperozide on biting behaviour and performance in restricted-fed pigs following regrouping. J Anim Sci 66:669–675
Carlsson A, Lindqvist M (1973) Effects of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol 25:437–444
Carlsson A, Corrodi H, Waldeck B (1963) a-Substituierte Dopacetamide als Hemmer der Catechol-O-Methyltransferase und der enzymatischen Hydroxylierung aromatischer Aminosäuren in den Catecholamin-Metabolismus eingreifende Substanzen. Helv Chim Acta 40:2271–2285
Christensson EG, Björk A, Gustafsson B, Magee I, Nerme V, Olsson N-G (1981) FG5606, a new antiaggressive compound with effects on different stress-induced disorders. IIIrd World Congress of Biological Psychiatry, Stockholm, Sweden, June 28–July 3 1981
Christensson EG, Gustafsson B (1985) Amperozide, a novel psychotropic compound with specific effect on limbic brain areas. Acta Physiol Scand 124:suppl 542:281
Corrodi H, Hanson LCF (1966) Central effects of an inhibitor of tyrosine hydroxylase. Psychopharmacologia (Berl) 10:116–125
Engel JA, Egbe P, Liljequist S, Söderpalm B (1989) Effects of amperozide in two animal models of anxiety. Acta Pharmacol Toxicol (in press)
Engström G, Svensson TH, Waldeck B (1974) Thyroxine and brain catecholamines increased transmitter synthesis and increased receptor sensitivity. Brain Res 72:471–483
Ferris RM, Tang FLM, Chang KJ, Russel A (1986) Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain. Life Sci 38, 2329
Florwall L, Corrodi H (1970) Dopamine β-hydroxylase inhibitors. Acta Pharmacol Suec 7:7–22
Gustafsson B, Christensson E (1989a) Amperozide — a new putative antipsychotic drug with a limbic mode of action in behavioural tests. Pharmacol Toxicol (in press)
Gustafsson B, Christensson E (1989b) Effects of amperozide on emotional behaviour. Pharmacol Toxicol (in press)
Haskins JT, Muth EA, Andree TH (1987) Biochemical and electrophysiological studies of the psychotropic compound, amperiozide. Brain Res Bull 19:465–471
Hellstrand K, Dellborg M (1981) Naloxone reverses reserpine induced hypokinesia in rats. J Pharm Pharmacol 33:599–600
Hunkler W, Möhler H, Pieri L, Pole P, Bonetti EP, Cumin R, Schaffner R, Haefely W (1981) Selective antagonists of benzodiazepines. Nature 290:514–516
Leysen JE, Gommeren W, Van Gompel P, Wijnants J, Janssen PFM, Laduron PM (1985) Receptor binding properties in vitro and in vivo of ritanserin: a very potent and long-acting serotonin-S2 antagonist. Mol Pharmacol 27:600–611
Nissbrandt H (1988) Dopamine synthesis, release and metabolism in rat substantia nigra. Thesis, University of Göteborg, ISBN, 91-7900-566-7
Olsen RW (1981) GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 37:1–13
Pettersson G, Johannessen K, Hulthe P, Engel J (1989) Effect of amperozide on the synthesis and turnover of monomines in rat brain. Pharmacol Toxicol (in press)
Svartengren J, Celander M (1988) Receptor binding properties of amperozide and reference drugs to 5-HT2, D2, α2 adrenergic and 5-HT1A receptors in rat CNS membranes. ESN 7th General Meeting, Göteborg, (Abstr) F292:176
Svartengren J, Christensson E (1985) Chronic amperozide treatment regulates 5-HT2-receptors labelled by 3H-ketanserin. Acta Physiol Scand 124: (Suppl 542) 221
Svartengren J, Simonsson P (1989) Receptor binding properties of amperozide. Pharmacol Toxicol (in press)
Svensson K (1986) Dopamine autoreceptor antagonists. A new class of central stimulants. Thesis, University of Göteborg, ISBN 917900-078-9
Svensson TH, Waldeck B (1969) On the significance of central noradrenaline for motor activity: experiments with a new dopamine β-hydroxylase inhibitor. Eur J Pharmacol 7:278–282
Svensson TH, Grenhoff J, Ugedo L (1988) Selective activation of mesolimbic dopamine neurones by amperozide, a putative antipsychotic drug. Soc Neurosci 18th Annual Meeting, Toronto, Abstr 164.3
Author information
Authors and Affiliations
Additional information
Send offprint requests to Nicholas Waters at the above address
Rights and permissions
About this article
Cite this article
Waters, N., Pettersson, G., Carlsson, A. et al. The putatively antipsychotic agent amperozide produces behavioural stimulation in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 340, 161–169 (1989). https://doi.org/10.1007/BF00168964
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00168964